466 related articles for article (PubMed ID: 34867942)
1. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
Sullivan PM; Reed SJ; Kalia V; Sarkar S
Front Immunol; 2021; 12():706150. PubMed ID: 34867942
[TBL] [Abstract][Full Text] [Related]
2. Tissue-resident memory CD8
Wang T; Shen Y; Luyten S; Yang Y; Jiang X
Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
[TBL] [Abstract][Full Text] [Related]
3. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
4. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
Front Immunol; 2020; 11():1109. PubMed ID: 32625204
[TBL] [Abstract][Full Text] [Related]
5. Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.
Monjazeb AM; Tietze JK; Grossenbacher SK; Hsiao HH; Zamora AE; Mirsoian A; Koehn B; Blazar BR; Weiss JM; Wiltrout RH; Sckisel GD; Murphy WJ
PLoS One; 2014; 9(8):e102709. PubMed ID: 25119341
[TBL] [Abstract][Full Text] [Related]
6. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
7. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
8. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment.
Qiao G; Chen M; Mohammadpour H; MacDonald CR; Bucsek MJ; Hylander BL; Barbi JJ; Repasky EA
Cancer Immunol Res; 2021 Jun; 9(6):651-664. PubMed ID: 33762351
[TBL] [Abstract][Full Text] [Related]
9. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Lanitis E; Rota G; Kosti P; Ronet C; Spill A; Seijo B; Romero P; Dangaj D; Coukos G; Irving M
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33156338
[TBL] [Abstract][Full Text] [Related]
10. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
[TBL] [Abstract][Full Text] [Related]
11. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies.
Watanabe K; Nishikawa H
Int Immunol; 2021 Oct; 33(11):551-562. PubMed ID: 34374779
[TBL] [Abstract][Full Text] [Related]
12. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
13. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.
Lee KJ; Choi D; Tae N; Song HW; Kang YW; Lee M; Moon D; Oh Y; Park S; Kim JH; Jeong S; Yang J; Park U; Hong DH; Byun MS; Park SH; Sohn J; Park Y; Im SK; Choi SS; Kim DH; Lee SW
Cell Rep Med; 2024 May; 5(5):101567. PubMed ID: 38744277
[TBL] [Abstract][Full Text] [Related]
14. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
15. Akt signaling is critical for memory CD8
Rogel A; Willoughby JE; Buchan SL; Leonard HJ; Thirdborough SM; Al-Shamkhani A
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1178-E1187. PubMed ID: 28137869
[TBL] [Abstract][Full Text] [Related]
16. [T cell-based immunotherapies in solid tumors].
Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
[TBL] [Abstract][Full Text] [Related]
17. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
18. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.
Dwyer CJ; Knochelmann HM; Smith AS; Wyatt MM; Rangel Rivera GO; Arhontoulis DC; Bartee E; Li Z; Rubinstein MP; Paulos CM
Front Immunol; 2019; 10():263. PubMed ID: 30842774
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
Huang H; Xiang J
Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
[TBL] [Abstract][Full Text] [Related]
20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
